Mazloom et al developed a prognostic score for patients with extranodal marginal zone lymphoma (MZL). This can help to identify a patient who may benefit from more aggressive management. The authors are from the University of Texas M.D. Anderson Cancer Center in Houston.
Parameters:
(1) serum beta-2 microglobulin concentration
(2) B symptoms
(3) gender
Parameter
Finding
Points
serum beta-2 microglobulin
< 2.5 mg/L
0
>= 2.5 mg/L
1
B symptoms
absent
0
present
1
gender
female
0
male
1
total score =
= SUM(points for all 3 parameters)
Interpretation:
• minimum score: 0
• maximum score: 3
• The higher the score the worse the prognosis.
Total Score
Risk Group
5 Year Recurrence Free Survival
5 Year Overall Survival
0
low
80%
96%
1
intermediate
71%
95%
2 or 3
high
44%
55%
To read more or access our algorithms and calculators, please log in or register.
